The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

Antibody-Drug Conjugates (ADC) Market- Driven by Advanced Payload Technologies and Strategic Industry Partnerships Sai Kumar DataM Intelligence 4market Research LLP +1 877-441-4866 ... Visit us on ...

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The FTSE 100 and European stocks were jittery on Friday, moving lower while US markets were closed for 4 July, as investors ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

London has struggled for several years to attract big-name IPOs amid a dearth of liquidity and a less favourable regulatory climate, with reforms last year so far failing to arrest the decline.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...